Volume 13, Number 1—January 2007

Research

Model for Assessing Human Papillomavirus Vaccination Strategies

Elamin H. Elbasha* , Erik J. Dasbach*, and Ralph P. Insinga*

Author affiliations: *Merck Research Laboratories, North Wales, Pennsylvania, USA;

Main Article

Figure 8

Figure 8. Impact of age that vaccination was begun on cervical cancer incidence due to human papillomavirus 16/18 infection among girls and women >12 years of age.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.